Travis J Hunt, Anna Berzkalns, Chase A Cannon, Tim W Menza, Julia C Dombrowski, Matthew R Golden
{"title":"利用公共卫生监测资料对晚期或不明病程潜伏性梅毒三种治疗方案的比较","authors":"Travis J Hunt, Anna Berzkalns, Chase A Cannon, Tim W Menza, Julia C Dombrowski, Matthew R Golden","doi":"10.1097/OLQ.0000000000002148","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The CDC recommends treating latent syphilis of late/unknown duration (LSUD) with three doses of intramuscular benzathine penicillin G (BPG) or twenty-eight days of oral doxycycline. This recommendation lacks high-quality evidence.</p><p><strong>Methods: </strong>Using public health surveillance data from King County, Washington, we conducted a retrospective cohort study comparing rates of serological cure (>2-titer RPR decline) among persons with LSUD following receipt of one of three regimens: one dose of BPG, three doses of BPG, and twenty-eight days of doxycycline. Subjects included persons diagnosed 2007-2020 with initial an RPR >1:2 and follow-up RPR testing 1-36 months post-treatment. We stratified initial RPRs into high- and low-titer (>1:32, <1:32) and compared outcomes using Cox proportional hazards.</p><p><strong>Results: </strong>The study population included 761 persons with median time from treatment to last RPR/serological cure of 219 days (IQR 114-488). Among high-titer persons, serological cure occurred in 36 (88%) of 41, 330 (88%) of 376, and 58 (88%) of 64 receiving single-dose BPG, three-dose BPG, and doxycycline, respectively. Among low-titer persons, serological cure occurred in 4 (31%) of 13, 114 (49%) of 235, and 14 (47%) of 30 receiving single-dose BPG, three-dose BPG, and doxycycline, respectively. Controlling for initial RPR, serological cure did not differ between high-titer persons receiving one- and three-dose BPG (aHR: 0.89; 95% CI: [0.63, 1.26]) or one-dose BPG and twenty-eight days of doxycycline (aHR: 1.03; 95% CI: [0.68, 1.58]).</p><p><strong>Conclusions: </strong>Serological outcomes in high-titer LSUD following one dose of BPG, three doses of BPG, and twenty-eight days of doxycycline are similar.</p>","PeriodicalId":21837,"journal":{"name":"Sexually transmitted diseases","volume":" ","pages":""},"PeriodicalIF":2.4000,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Comparison of Three Treatment Regimens for Latent Syphilis of Late or Unknown Duration Using Public Health Surveillance Data.\",\"authors\":\"Travis J Hunt, Anna Berzkalns, Chase A Cannon, Tim W Menza, Julia C Dombrowski, Matthew R Golden\",\"doi\":\"10.1097/OLQ.0000000000002148\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>The CDC recommends treating latent syphilis of late/unknown duration (LSUD) with three doses of intramuscular benzathine penicillin G (BPG) or twenty-eight days of oral doxycycline. This recommendation lacks high-quality evidence.</p><p><strong>Methods: </strong>Using public health surveillance data from King County, Washington, we conducted a retrospective cohort study comparing rates of serological cure (>2-titer RPR decline) among persons with LSUD following receipt of one of three regimens: one dose of BPG, three doses of BPG, and twenty-eight days of doxycycline. Subjects included persons diagnosed 2007-2020 with initial an RPR >1:2 and follow-up RPR testing 1-36 months post-treatment. We stratified initial RPRs into high- and low-titer (>1:32, <1:32) and compared outcomes using Cox proportional hazards.</p><p><strong>Results: </strong>The study population included 761 persons with median time from treatment to last RPR/serological cure of 219 days (IQR 114-488). Among high-titer persons, serological cure occurred in 36 (88%) of 41, 330 (88%) of 376, and 58 (88%) of 64 receiving single-dose BPG, three-dose BPG, and doxycycline, respectively. Among low-titer persons, serological cure occurred in 4 (31%) of 13, 114 (49%) of 235, and 14 (47%) of 30 receiving single-dose BPG, three-dose BPG, and doxycycline, respectively. Controlling for initial RPR, serological cure did not differ between high-titer persons receiving one- and three-dose BPG (aHR: 0.89; 95% CI: [0.63, 1.26]) or one-dose BPG and twenty-eight days of doxycycline (aHR: 1.03; 95% CI: [0.68, 1.58]).</p><p><strong>Conclusions: </strong>Serological outcomes in high-titer LSUD following one dose of BPG, three doses of BPG, and twenty-eight days of doxycycline are similar.</p>\",\"PeriodicalId\":21837,\"journal\":{\"name\":\"Sexually transmitted diseases\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":2.4000,\"publicationDate\":\"2025-03-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Sexually transmitted diseases\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1097/OLQ.0000000000002148\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Sexually transmitted diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/OLQ.0000000000002148","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
Comparison of Three Treatment Regimens for Latent Syphilis of Late or Unknown Duration Using Public Health Surveillance Data.
Background: The CDC recommends treating latent syphilis of late/unknown duration (LSUD) with three doses of intramuscular benzathine penicillin G (BPG) or twenty-eight days of oral doxycycline. This recommendation lacks high-quality evidence.
Methods: Using public health surveillance data from King County, Washington, we conducted a retrospective cohort study comparing rates of serological cure (>2-titer RPR decline) among persons with LSUD following receipt of one of three regimens: one dose of BPG, three doses of BPG, and twenty-eight days of doxycycline. Subjects included persons diagnosed 2007-2020 with initial an RPR >1:2 and follow-up RPR testing 1-36 months post-treatment. We stratified initial RPRs into high- and low-titer (>1:32, <1:32) and compared outcomes using Cox proportional hazards.
Results: The study population included 761 persons with median time from treatment to last RPR/serological cure of 219 days (IQR 114-488). Among high-titer persons, serological cure occurred in 36 (88%) of 41, 330 (88%) of 376, and 58 (88%) of 64 receiving single-dose BPG, three-dose BPG, and doxycycline, respectively. Among low-titer persons, serological cure occurred in 4 (31%) of 13, 114 (49%) of 235, and 14 (47%) of 30 receiving single-dose BPG, three-dose BPG, and doxycycline, respectively. Controlling for initial RPR, serological cure did not differ between high-titer persons receiving one- and three-dose BPG (aHR: 0.89; 95% CI: [0.63, 1.26]) or one-dose BPG and twenty-eight days of doxycycline (aHR: 1.03; 95% CI: [0.68, 1.58]).
Conclusions: Serological outcomes in high-titer LSUD following one dose of BPG, three doses of BPG, and twenty-eight days of doxycycline are similar.
期刊介绍:
Sexually Transmitted Diseases, the official journal of the American Sexually Transmitted Diseases Association, publishes peer-reviewed, original articles on clinical, laboratory, immunologic, epidemiologic, behavioral, public health, and historical topics pertaining to sexually transmitted diseases and related fields. Reports from the CDC and NIH provide up-to-the-minute information. A highly respected editorial board is composed of prominent scientists who are leaders in this rapidly changing field. Included in each issue are studies and developments from around the world.